Break out: Urogenital schistosomiasis and Schistosoma haematobium infection in the post-genomic era by Brindley, Paul J. & Hotez, Peter J.
Himmelfarb Health Sciences Library, The George Washington University
Health Sciences Research Commons
Microbiology, Immunology, and Tropical Medicine
Faculty Publications Microbiology, Immunology, and Tropical Medicine
3-2013
Break out: Urogenital schistosomiasis and






Follow this and additional works at: http://hsrc.himmelfarb.gwu.edu/smhs_microbio_facpubs
Part of the Medical Immunology Commons, Medical Microbiology Commons, Parasitic
Diseases Commons, and the Parasitology Commons
This Journal Article is brought to you for free and open access by the Microbiology, Immunology, and Tropical Medicine at Health Sciences Research
Commons. It has been accepted for inclusion in Microbiology, Immunology, and Tropical Medicine Faculty Publications by an authorized
administrator of Health Sciences Research Commons. For more information, please contact hsrc@gwu.edu.
Recommended Citation
Brindley, P.J. & Hotez, P.J. (2013). Break out: Urogenital schistosomiasis and Schistosoma haematobium infection in the post-genomic
era. PLoS Neglected Tropical Diseases, 7(3), article number e1961.
Editorial
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The newly completed whole genome sequence of
Schistosoma haematobium, the leading cause
of human schistosomiasis and an emerging co-
factor in Africa’s AIDS and cancer epidemics,
together with rapidly advancing genetic manipula-
tion technologies, is providing new insights that
could lead to the development of a new generation
of tools for eliminating this ancient scourge.
Today, more than 90% of the roughly
200 million cases of schistosomiasis occur
in Africa [1,2], of which approximately
two-thirds are caused by Schistosoma haema-
tobium [3], the etiologic agent of urogenital
schistosomiasis. More recently, Charles
King and his colleagues have suggested
that the number of cases of S. haematobium
may be much greater than previously
believed, even possibly double or triple
that of earlier prevalence estimates [4]. If
confirmed, urogenital schistosomiasis may
represent the most common infection or
even adverse health condition in sub-
Saharan Africa.
Urogenital schistosomiasis results when
adult female S. haematobium worm pairs
living in the veins draining key pelvic
organs, including the bladder, uterus, and
cervix, release terminal-spine eggs that
penetrate the tissues and are excreted in in
the urine to allow propagation of the
parasite life cycle. However, many schis-
tosome eggs fail to exit the body, and
come to embolize within the capillary beds
of pelvic end-organs, especially the tissues
of the bladder, ureters, and female and
male genital organs. Here they induce
granulomas and ultimately small fibrotic
nodules known as ‘‘sandy patches’’ [5].
Numerous granulomas and sandy patches
cause bladder and ureteral inflammation
associated with hematuria in more than
50% of the cases [3], in addition to organ
deformities associated with ureteric ob-
struction, secondary urinary tract and
renal infections, hydronephrosis, and ulti-
mately renal failure in millions of people
living in Africa [5].
Up to 75% of girls and women with
chronic S. haematobium infection will also
experience deposition of eggs with granu-
lomas and sandy patches on their uterus,
cervix, and lower genital tract [6,7]. The
resulting female genital schistosomiasis
(FGS) is associated with contact bleeding,
discharge, pain on intercourse, and sec-
ondary infections and diminished fertility;
it is also a source of shame and stigma
[6,7]. FGS is not a rare condition—one
estimate suggested that of the estimated 70
million children currently infected with S.
haematobium, approximately 19 million girls
and women will eventually develop FGS
in the coming decade [8]. However, these
numbers are likely conservative estimates,
such that FGS may represent one of the
most common gynecological conditions in
Africa.
In addition to the pathologies outlined
above, the effects of chronic S. haematobium
infection in children have been linked to
chronic inflammation and pain, as well as
growth stunting and cognitive deficits
among tens of millions of children [4].
FGS has also been identified as a co-factor
in Africa’s AIDS epidemic, especially in
Zimbabwe and Tanzania, where it was
linked to a 3–4 times increased risk in
acquiring HIV infection [6–8]. S. haemato-
bium eggs have now been further identified
as a Group 1 carcinogen responsible for a
unique squamous cell carcinoma, which is
widespread in S. haematobium–endemic
areas [5,9]. S. haematobium also exerts
important host endocrine effects based in
part on its ability to synthesize and release
estradiol [9]. A full consideration of these
and other chronic morbidities that use
disability-adjusted life years (DALYs) as a
metric suggests that chronic urogenital
schistosomiasis may equal or even exceed
malaria or other better-known conditions
in terms of its disease burden in Africa [4].
Despite its overwhelming public health
importance and its well-established links to
HIV/AIDS and cancer, S. haematobium has
been labeled ‘‘the neglected schistosome’’
[10,11]. Indeed, as shown in Table 1, a
search of the literature named in PubMed
(the online database of the US National
Library of Medicine) supports this asser-
tion. Over the last five years, there have
been 644 papers listed in PubMed per
million cases of Asian schistosomiasis
caused by Schistosoma japonicum and 25
papers per million cases of S. mansoni
infection, Africa’s other major schisto-
some. In contrast, only three papers per
million cases of S. haematobium infection
have appeared in PubMed over the last
five years. (The 342 publications over the
past five years investigating S. haematobium
and schistosomiasis haematobia represent
challenging research; and much effort
went into studies on this organism during
the several decades before that. Much of
this work was undertaken with humans as
the host, compounding the challenges for
the research and encumbering progress.
Although a review of this literature is
beyond the aim of our editorial, studies
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such as those by Agnew, Cheever, and
Doenhoff on rodent models of infection
[12,13]; Capron and co-workers on vac-
cines [14]; Feldmeier, Kjetland, Shiff, and
others on female genital schistosomiasis
and bladder cancer [7,9,15]; Brooker,
Deelder, Hamburger, Mutapi, Sturrock,
and others on epidemiology, co-infections,
and diagnostics [3,16–18]; and Kitron,
Loker, and Rollinson on intermediate host
snails, ecology, and evolutionary aspects
[10,19,20] have provided crucial scaffolds,
the ‘‘shoulders of giants’’ as it were.
Investigators accessing the newly available
genetic tools can now gaze from these
shoulders and hopefully move rapidly to
new interventions for S. haematobium infec-
tion. [We apologize to investigators we did
not have space to mention.])
Nonetheless, the field of S. haematobium
research, in contrast to studies for the
other schistosomes, has largely remained
‘‘on the outside looking in’’ with respect to
breakthroughs in the areas of omics, high
throughput drug screening, reverse vacci-
nology, molecular imaging, bioengineer-
ing, structural biology, and molecular
immunology. Whereas some of the dearth
in scientific activity and productivity for
urogenital schistosomiasis can be ascribed
to the fact simply that it is a neglected
tropical disease, this observation cannot
explain why research on S. japonicum and
Schistosoma mansoni has been more active
and fruitful. It is plausible that the
following factors are responsible for this
situation: 1) the absence of mouse animal
models; 2) the absence of in vitro systems;
and 3) the absence of a completed genome
projects and related omics projects.
The good news is that studies conducted
within the past two years suggest that
many of these barriers have now been
surmounted either completely or partially
and that there is a path forward to
facilitate a new era of S. haematobium
research.
1. Animal models of infection. The availability
of mouse models for S. mansoni and S.
japonicum infections has stimulated at
least two generations of molecular and
cellular immunologists to undertake
groundbreaking studies on these two
helminthiases and to unravel the com-
plexities of schistosome-mediated im-
munopathogenesis [21–23]. Within the
last two years (2011–2012), key studies
have been conducted in genetically
modified knock-out mice to also iden-
tify co-factors, leading to improved
understanding of S. haematobium carci-
nogenesis [24], while microinjection of
S. haematobium eggs in the bladder of
mice has been shown to reproduce
urinary tract fibrosis and other bladder
histopathologic changes typically found
in human urogenital schistosomiasis
[25]. Expansion of such studies, in-
cluding work in humanized mouse
models, will undoubtedly produce
new insights into parasite-induced im-
munopathogenesis, carcinogenesis,
FGS, and HIV/AIDS co-infections.
2. In vitro systems. The first report of the
genetic manipulation of S. haematobium
by short interfering ribonucleic acids
(siRNAs) into parasite eggs, and subse-
quent culturing of eggs, miracidia,
schistosomula, and adult schistosomes
[11], portend enormous promise for
analyzing novel S. haematobium genes.
Such in vitro studies would comple-
ment ongoing in vivo projects in mice
as outlined above. Simultaneously,
work in mammalian cell lines and
transgenic schistosomes will provide
additional insights into parasite-medi-
ated carcinogenesis [26,27].
3. Omics. In 2012, the 385-Mb genome of
S. haematobium was completed at 74-fold
coverage [28–30]. While there was a
high synteny between the roughly
13,000 genes of S. haematobium and the
other two schistosomes, a number of
unique S. haematobium genes were
identified, including genes encoding
novel drug targets, estrogen-synthesiz-
ing enzymes that might be involved in
neocarcinogenesis of eggs in situ, and
molecules with immunomodulatory
functions.
It is particularly promising and of great
importance that the development of
mouse models for S. haematobium infections
is maturing roughly in parallel with the
development of in vitro technologies for
parasite gene manipulation together with
the completion of whole genome sequenc-
ing for S. haematobium. Assuming additional
proteomic and metabolomics projects for
S. haematobium move forward, together with
epigenetic studies and advances with in
vitro methods linked to RNAi and trans-
genesis, the next few years could become a
watershed for S. haematobium research. In
so doing, we can anticipate striking new
insights into parasite-induced carcinogen-
esis and HIV/AIDS co-infections that
result from urogenital schistosomiasis.
Breakthroughs in S. haematobium studies
will require international cooperation and
a new level of support. The community of
S. haematobium researchers is not numeri-
cally large, but could easily embrace
scientists working on other schistosomes
as well as those involved in cancer and
AIDS research. One way to proceed is to
establish a consortium of S. haematobium
investigators and projects, possibly
through joint funding from the US
National Cancer Institute, National Insti-
tute of Allergy and Infectious Disease
(NIAID) and/or other institutes or centers
of the National Institutes of Health (NIH),
the Wellcome Trust, European Union and
government support, and possibly private
donors such as the Bill & Melinda Gates
Foundation. We believe that no one
agency will likely do it all in terms of
significantly advancing the S. haematobium
research and development agenda. We
also note that, with taxpayer-funded
support from the NIAID-NIH, an Egyp-
tian strain of S. haematobium and its
intermediate host snail Bulinus truncatus
reagents are available to interested inves-
tigators anywhere in the world from the





Citations over the Last
Five Yearsb
PubMed Citations per
Millions of Human Cases References
Schistosoma japonicum 1 million 644 644 Steinmann et al. 2006 [1]
Schistosoma mansoni 54 milliona 1,371 25 Van der Werf et al. 2003 [3]
Schistosoma haematobium 112 milliona 342 3 Van der Werf et al. 2003 [3]
aSub-Saharan Africa only.
bSearch conducted on July 14, 2012.
doi:10.1371/journal.pntd.0001961.t001
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BEI Resources catalog of the American
Type Culture Collection [31].
In 2012, the global community respond-
ed to the call that ‘‘Africa is desperate for
praziquantel’’ [32], with an unprecedent-
ed commitment of praziquantel donations
from Merck KgaA and a London Decla-
ration as a first step for the elimination of
schistosomiasis as a public health problem
[33]. While the drug donations and a
subsequent 26 May 2012 World Health
Assembly resolution calling for schistoso-
miasis elimination [34] are essential, we
feel that alone such measures will not
address Africa’s burden of S. haematobium–
induced cancer nor the stealth role of S.
haematobium in promoting Africa’s AIDS
epidemic. In parallel, there needs to be put
in place an aggressive program of research
and development that includes fundamen-
tal studies and translational approaches
toward development of new diagnostics,
drugs, and vaccines. Basic research con-
ducted within the last two years has now
set the stage to go that extra mile.
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